CN103497212B - A kind of preparation method of rosuvastain calcium intermediate - Google Patents

A kind of preparation method of rosuvastain calcium intermediate Download PDF

Info

Publication number
CN103497212B
CN103497212B CN201310439485.XA CN201310439485A CN103497212B CN 103497212 B CN103497212 B CN 103497212B CN 201310439485 A CN201310439485 A CN 201310439485A CN 103497212 B CN103497212 B CN 103497212B
Authority
CN
China
Prior art keywords
methyl
fluorophenyl
pyrimidine
sec
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310439485.XA
Other languages
Chinese (zh)
Other versions
CN103497212A (en
Inventor
蒋成君
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Lover Health Science and Technology Development Co Ltd
Original Assignee
Zhejiang Lover Health Science and Technology Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Lover Health Science and Technology Development Co Ltd filed Critical Zhejiang Lover Health Science and Technology Development Co Ltd
Priority to CN201310439485.XA priority Critical patent/CN103497212B/en
Publication of CN103497212A publication Critical patent/CN103497212A/en
Application granted granted Critical
Publication of CN103497212B publication Critical patent/CN103497212B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention discloses a kind of preparation method of rosuvastain calcium intermediate.4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methyl alcohol is joined in solvent; cool to-5 ~ 10 DEG C; add (R)-3-[(t-butyldimethylsilyi) oxygen base]-5-oxo-6-triphenylphosphine hecanoic acid t-butyl ester; add NiNPs; 50-80 DEG C of reaction 15 ~ 24 hours; filter; filtrate reduced in volume; silicagel column on resistates; with trichloromethane wash-out, concentrating under reduced pressure obtains yellow oil dress liquid.Raw material of the present invention is simple, and reaction conditions is gentle, and environmental friendliness, may be used for industrialized production.

Description

A kind of preparation method of rosuvastain calcium intermediate
Technical field
The present invention relates to the synthesis technique of compound, particularly relate to a kind of preparation method of rosuvastain calcium intermediate.
Background technology
7-[4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-base]-(3R)-3-(t-butyldimethylsilyi)-5-oxo-6-heptanoic acid tert-butyl ester is the key intermediate (CurrentOrganicChemistry in synthesizing rosuvastatin spit of fland; 2010; 14,816-845).(Jiangsu pharmacy and the clinical study such as Cai Wei, 2005, 13(4) 8-10) report a kind of 6-[(1E)-2-[4-(4-fluorophenyl)-6-sec.-propyl-2-[methyl (methylsulfonyl) is amino]-5-pyrimidine] vinyl]-2, 2-dimethyl-1, the synthetic method of 3-dioxane-4-methyl acetate, with 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-formaldehyde for starting raw material, condensation reaction preparation is carried out with (R)-3-[(t-butyldimethylsilyi) oxygen base]-5-oxo-6-triphenylphosphine methyl caproate.CN102617481 is by synthesis 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methanol-fueled CLC 7-[4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-base]-(3R)-3-(t-butyldimethylsilyi)-5-oxo-6-heptanoic acid tert-butyl ester.Japan Shionogi institute (US5260440) with 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-formaldehyde for raw material; Reactive Synthesis 6-[(1E)-2-[4-(4-fluorophenyl)-6-sec.-propyl-2-[methyl (methylsulfonyl) is amino]-5-pyrimidine] vinyl]-2 is wished by ladder Wei; 2-dimethyl-1,3-dioxane-4-methyl acetate.NataliaAndrushko(Eur.J.Org.Chem.; 2008; 847-853) synthesize 6-[(1E)-2-[4-(4-fluorophenyl)-6-sec.-propyl-2-[methyl (methylsulfonyl) is amino]-5-pyrimidine] vinyl]-2 with same route; 2-dimethyl-1; 3-dioxane-4-methyl acetate, has synthesized 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-formaldehyde unlike NataliaAndrushko by palladium chtalyst formylation.As from the foregoing, 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-formaldehyde synthesizes the most basic raw material in fact of 7-[4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl l-N-methane sulfonylamino) pyrimidine-5-base]-(3R)-3-(t-butyldimethylsilyi)-5-oxo-6-heptanoic acid tert-butyl ester.Usually Swern(R.E.Ireland, D.W.Norbeck, J.Org.Chem.1985 is passed through by 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methyl alcohol, 50,2198 – 2200.), MnO 2(R.J.K.Taylor, M.Reid, J.Foot, S.A.406Raw, Acc.Chem.Res.2005, 38, 851 – 869), Dess-Martin(A.G.M.Barrett, D.Hamprecht, M.Ohkubo, J.Org.Chem.1997, 62, 9376 – 9378.), BaMnO4(S.Shuto, S.Niizuma, A.Matsuda, J.Org.Chem.1998, 63, 4114489 – 4493.), IBX(A.Maiti, J.S.Yadav, Synth.Commun.2001, 31, 1499 – 1506.), TPAP(R.N.MacCoss, E.P.Balskus, S.V.Ley, TetrahedronLett.2003, 44, 7779 – 7781.), PCC(A.R.Bressette, L.C.GloverIV, Synlett2004, 738 – 740), SO3.Py(F.R.PinachoCrisostomo, R.Carrillo, T.Martin, F.Garcia-Tellado, V.S.Martin, J.Org.Chem.2005, 70, 10099 – 10101) or TEMPO(J.M.Vatele, TetrahedronLett.2006, 47, 715 – 718.) oxidation obtain.These method choice are poor, and produce a large amount of waste water,waste gas and industrial residue, environment is unfriendly.
Summary of the invention
The object of the invention is to overcome the deficiencies in the prior art, a kind of preparation method of rosuvastain calcium intermediate is provided.
A kind of preparation method of rosuvastain calcium intermediate is: join in solvent by 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methyl alcohol, cool to-5 ~ 10 DEG C, add (R)-3-[(t-butyldimethylsilyi) oxygen base]-5-oxo-6-triphenylphosphine hecanoic acid t-butyl ester, 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methyl alcohol is 1:1 ~ 1.05 with the mol ratio of (R)-3-[(t-butyldimethylsilyi) oxygen base]-5-oxo-6-triphenylphosphine hecanoic acid t-butyl ester, add NiNPs, the mass ratio of 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methyl alcohol and NiNPs is 1:0.1 ~ 0.2, 50-80 DEG C of reaction 15 ~ 24 hours, filter, filtrate reduced in volume, silicagel column on resistates, with trichloromethane wash-out, concentrating under reduced pressure obtains 7-[4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-base]-(3R)-3-(t-butyldimethylsilyi)-5-oxo-6-heptanoic acid tert-butyl ester.Described solvent is tetrahydrofuran (THF) or 2-methyltetrahydrofuran; Described NiNPs is the nano-nickel powder of 30-60nm or 60-100nm.
Raw material of the present invention is simple, and reaction conditions is gentle, and environmental friendliness, may be used for industrialized production.
Embodiment
Reaction equation of the present invention is as follows:
A kind of preparation method of rosuvastain calcium intermediate is: join in solvent by 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methyl alcohol, cool to-5 ~ 10 DEG C, add (R)-3-[(t-butyldimethylsilyi) oxygen base]-5-oxo-6-triphenylphosphine hecanoic acid t-butyl ester, 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methyl alcohol is 1:1 ~ 1.05 with the mol ratio of (R)-3-[(t-butyldimethylsilyi) oxygen base]-5-oxo-6-triphenylphosphine hecanoic acid t-butyl ester, add NiNPs, the mass ratio of 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methyl alcohol and NiNPs is 1:0.1 ~ 0.2, 50-80 DEG C of reaction 15 ~ 24 hours, filter, filtrate reduced in volume, silicagel column on resistates, with trichloromethane wash-out, concentrating under reduced pressure obtains 7-[4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-base]-(3R)-3-(t-butyldimethylsilyi)-5-oxo-6-heptanoic acid tert-butyl ester.Described solvent is tetrahydrofuran (THF) or 2-methyltetrahydrofuran; Described NiNPs is the nano-nickel powder of 30-60nm or 60-100nm.
Embodiment 1
In the there-necked flask of 250ml, load onto thermometer, pH meter and constant pressure funnel and magnetic agitation.Under normal temperature, tetrahydrofuran (THF) 50ml is added in reaction flask, add 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methyl alcohol 35.3 grams again, cool to 10 DEG C, add (R)-3-[(t-butyldimethylsilyi) oxygen base]-5-oxo-6-triphenylphosphine hecanoic acid t-butyl ester 50.8 grams, add the NiNPs of 7.06 grams of 60-100nm, 50 DEG C of reactions 24 hours, filter, filtrate reduced in volume, silicagel column on resistates, with trichloromethane wash-out, concentrating under reduced pressure obtains yellow oil dress liquid 7-[4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-base]-(3R)-3-(t-butyldimethylsilyi)-5-oxo-6-heptanoic acid tert-butyl ester 43.9 grams, yield 69.1%.
1H-NMR(CDCl 3)δ:0.05(3H,s,SiCH 3),0.061(3H,s,SiCH 3,0.80(9H,s,Si(CH 3) 3)),1.28(6H,d,J=7),2.48(2H,m),2.74(2H,m),3.36(1H,hept,J=7),3.51(3H,s),3.59(3H,s),3.69(9H,s),4.59(1H,m),6.51(1H,dd,J=6,16),7.11(2H,m),7.58(2H,m),7.60(1H,d,J=16).
Embodiment 2
In the there-necked flask of 250ml, load onto thermometer, pH meter and constant pressure funnel and magnetic agitation.Under normal temperature, 2-methyltetrahydrofuran 50ml is added in reaction flask, add 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methyl alcohol 35.3 grams again, cool to-5 DEG C, add (R)-3-[(t-butyldimethylsilyi) oxygen base]-5-oxo-6-triphenylphosphine hecanoic acid t-butyl ester 48.4 grams, add the NiNPs of 3.53 grams of 30-60nm, 80 DEG C of reactions 15 hours, filter, filtrate reduced in volume, silicagel column on resistates, with trichloromethane wash-out, concentrating under reduced pressure obtains yellow oil dress liquid 7-[4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-base]-(3R)-3-(t-butyldimethylsilyi)-5-oxo-6-heptanoic acid tert-butyl ester 45.6 grams, yield 71.8%.
Embodiment 3
In the there-necked flask of 250ml, load onto thermometer, pH meter and constant pressure funnel and magnetic agitation.Under normal temperature, tetrahydrofuran (THF) 100ml is added in reaction flask, add 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methyl alcohol 35.3 grams again, cool to 0 DEG C, add (R)-3-[(t-butyldimethylsilyi) oxygen base]-5-oxo-6-triphenylphosphine hecanoic acid t-butyl ester 50.0 grams, add the NiNPs of 5.29 grams of 30-60nm, 60 DEG C of reactions 20 hours, filter, filtrate reduced in volume, silicagel column on resistates, with trichloromethane wash-out, concentrating under reduced pressure obtains yellow oil dress liquid 7-[4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-base]-(3R)-3-(t-butyldimethylsilyi)-5-oxo-6-heptanoic acid tert-butyl ester 49.8 grams, yield 77.6%.

Claims (2)

1. the preparation method of a rosuvastain calcium intermediate, it is characterized in that comprising the steps: 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methyl alcohol to join in solvent, cool to-5 ~ 10 DEG C, add (R)-3-[(t-butyldimethylsilyi) oxygen base]-5-oxo-6-triphenylphosphine hecanoic acid t-butyl ester, 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methyl alcohol is 1:1 ~ 1.05 with the mol ratio of (R)-3-[(t-butyldimethylsilyi) oxygen base]-5-oxo-6-triphenylphosphine hecanoic acid t-butyl ester, add NiNPs, the mass ratio of 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-methyl alcohol and NiNPs is 1:0.1 ~ 0.2, 50-80 DEG C of reaction 15 ~ 24 hours, filter, filtrate reduced in volume, silicagel column on resistates, with trichloromethane wash-out, concentrating under reduced pressure obtains 7-[4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methane sulfonylamino) pyrimidine-5-base]-(3R)-3-(t-butyldimethylsilyi)-5-oxo-6-heptanoic acid tert-butyl ester, described NiNPs is the nano-nickel powder of 30-60nm or 60-100nm.
2. the preparation method of a kind of rosuvastain calcium intermediate according to claim 1, is characterized in that described solvent is tetrahydrofuran (THF) or 2-methyltetrahydrofuran.
CN201310439485.XA 2013-09-25 2013-09-25 A kind of preparation method of rosuvastain calcium intermediate Expired - Fee Related CN103497212B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310439485.XA CN103497212B (en) 2013-09-25 2013-09-25 A kind of preparation method of rosuvastain calcium intermediate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310439485.XA CN103497212B (en) 2013-09-25 2013-09-25 A kind of preparation method of rosuvastain calcium intermediate

Publications (2)

Publication Number Publication Date
CN103497212A CN103497212A (en) 2014-01-08
CN103497212B true CN103497212B (en) 2015-11-18

Family

ID=49862492

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310439485.XA Expired - Fee Related CN103497212B (en) 2013-09-25 2013-09-25 A kind of preparation method of rosuvastain calcium intermediate

Country Status (1)

Country Link
CN (1) CN103497212B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106632078B (en) * 2016-11-11 2019-05-07 上海雅本化学有限公司 A kind of refining methd of rosuvastain calcium intermediate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1415591A (en) * 2001-10-30 2003-05-07 中国石油化工股份有限公司 Technical method of dehydrogenating alcohols
CN1958593A (en) * 2005-11-03 2007-05-09 上海医药工业研究院 Method for preparing intermediate of synthesizing rosuvastatin calcium
EP2093230A1 (en) * 2007-04-18 2009-08-26 Teva Pharmaceutical Industries Ltd. A process for preparing intermediates of HMG-CoA reductase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1415591A (en) * 2001-10-30 2003-05-07 中国石油化工股份有限公司 Technical method of dehydrogenating alcohols
CN1958593A (en) * 2005-11-03 2007-05-09 上海医药工业研究院 Method for preparing intermediate of synthesizing rosuvastatin calcium
EP2093230A1 (en) * 2007-04-18 2009-08-26 Teva Pharmaceutical Industries Ltd. A process for preparing intermediates of HMG-CoA reductase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
瑞舒伐他汀中间体的合成工艺改进;邵飞等;《精细化工》;20060228;第23卷(第2期);第192-194页 *
瑞舒伐他汀合成路线图解;刘国庆等;《中国医药工业杂志》;20051231;第36卷(第9期);第585-586页 *

Also Published As

Publication number Publication date
CN103497212A (en) 2014-01-08

Similar Documents

Publication Publication Date Title
Yu et al. Visible Light‐Induced Methoxycarbonyldifluoromethylation of Trimethylsilyl Enol Ethers and Allyltrimethylsilanes with FSO2CF2CO2Me
CN103497212B (en) A kind of preparation method of rosuvastain calcium intermediate
JP5304818B2 (en) Process for producing 4-substituted or unsubstituted tetrahydropyran-4-carboxylic acid compound or ester compound thereof
CN100432038C (en) Method for producing nitrile compound, carboxylic acid compound or carboxylate compound
JP6212429B2 (en) Process for producing 1,3,4,5-tetracaffeoylquinic acid and intermediate compounds
PH12021550647A1 (en) Methods of producing pyrazole compounds
Khrustalevb Synthesis of dibenzopiperidinoaza-14-crown-4 ethers and their one-step conversion into dibenzo-16-crown-3
CA2732984A1 (en) Process for production of bicyclo[2.2.2]octylamine derivative
JP6158293B2 (en) Process for producing cis-alkoxy-substituted spirocyclic phenylacetylamino acid esters and cis-alkoxy-substituted spirocyclic 1H-pyrrolidine-2,4-dione derivatives
CN106045914A (en) Method for synthesizing tri-substituted imidazole compounds
JP6637880B2 (en) 5- (trifluoromethyl) pyrimidine derivative and method for producing the same
KR20120022757A (en) Method for producing 2-halogeno-6-substituted-4-trifluoromethylpyridine
JP2010235453A (en) Method for producing platinum complex
JP2006249004A (en) 2-(4-cyanotetrahydropyran-4-yl)-2-oxoacetic acid ester and method for producing the same
JP2011098949A (en) Process for producing carbonate ester
KR100968576B1 (en) Process of preparing 2-acyl-3-amino-2-alkenoate
JP6262079B2 (en) 4- (2,2,2-trifluoroethoxy) -5- (trifluoromethyl) pyrimidine derivative and method for producing the same
JP6139667B2 (en) Method for producing 3,4,5-tricaffeoylquinic acid
WO2024152408A1 (en) Alkylzinc reagent, and preparation method therefor and use thereof
EP1700852A1 (en) Processes for producing alkyl 3-(4-tetrahydropyranyl)-3-oxopropionate compound and 4-acyltetrahydropyran
CN104193692A (en) Synthesis method of triazine analogues
CN105237432A (en) Synthesis method of N,N-methylene-bis-benzamide compounds
KR20140063792A (en) Method of producing 2-oxo-2h-cyclohepta[b]furan analogue
KR101429543B1 (en) A novel crystal form of cabazitaxel and a method for preparing the same
JP2005075734A (en) Method for producing optically active homocitric acid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151118

Termination date: 20160925

CF01 Termination of patent right due to non-payment of annual fee